Who
Mika K. Derynck
Director
Company insider
Files Form 4 as: Director, Enliven Therapeutics.
In numbers
- Trades disclosed
- 25
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $19.1M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 23 Feb 2023
- Last trade
- 4 Aug 2026
- Last filed
- 6 Aug 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Aug 2026filed 6 Aug 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code M | $217K87,373 at $2.48 | filing |
| 4 Aug 2026filed 6 Aug 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code M | $697K27,567 at $25.28 | filing |
| 4 Aug 2026filed 6 Aug 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code M | $347K23,364 at $14.85 | filing |
| 4 Aug 2026filed 6 Aug 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —87,373 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,567 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —23,364 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,491 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code M | $460K20,491 at $22.47 | filing |
| 4 Aug 2026filed 6 Aug 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $9.6M158,795 at $60.21 | filing |
| 4 Aug 2026filed 6 Aug 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —87,373 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,567 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —23,364 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,491 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code M | $217K87,373 at $2.48 | filing |
| 4 Aug 2026filed 6 Aug 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code M | $697K27,567 at $25.28 | filing |
| 4 Aug 2026filed 6 Aug 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code M | $347K23,364 at $14.85 | filing |
| 4 Aug 2026filed 6 Aug 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code M | $460K20,491 at $22.47 | filing |
| 4 Aug 2026filed 6 Aug 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $9.6M158,795 at $60.21 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,126 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,126 at $0.00 | filing |
News
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst SaysELVN · dailypolitical.com · 21 Oct 2026Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearELVN · prnewswire.com · 14 Oct 2026
0 headlines in the last 90 days name Mika K. Derynck; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.